| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 0 | ||||
| Sells | 9 | -323K | 100% | $30.23 | -$9.75M |
| Net | -9 | -323K | -100% | -$9.75M |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Roivant Sciences Ltd. | Director, 10%+ Owner | $3.03B | Oct 2, 2023 | ||
| Peter Salzmann | Chief Executive Officer, Director | $24.9M | -$3.94M | -13.7% | Nov 20, 2024 |
| Frank Torti | Director | $23M | Apr 2, 2024 | ||
| Julia G. Butchko | Chief Development Officer | $14.3M | -$775K | -5.16% | Aug 21, 2024 |
| William L. Macias | Chief Medical Officer | $9.21M | -$799K | -7.98% | Nov 20, 2024 |
| Eva Renee Barnett | Chief Financial Officer | $8.43M | -$1.54M | -15.5% | Nov 20, 2024 |
| Mark S. Levine | Chief Legal Officer | $8.12M | -$1.28M | -13.6% | Nov 20, 2024 |
| George V. Migausky | Director | $4.38M | Apr 2, 2024 | ||
| Jay S. Stout | Chief Technology Officer | $4.2M | -$368K | -8.06% | Oct 23, 2024 |
| Michael Geffner | Chief Medical Officer | $3.99M | -$667K | -14.3% | Oct 23, 2024 |
| Andrew J. Fromkin | Director | $3.61M | Apr 2, 2024 | ||
| Douglas J. Hughes | Director | $3.41M | -$155K | -4.34% | Dec 2, 2024 |
| Melanie Gloria | Chief Operating Officer | $3.25M | Nov 18, 2024 | ||
| Christopher Van Tuyl | Chief Legal Officer | $3.14M | Dec 16, 2024 | ||
| Atul Pande | Director | $3.04M | -$221K | -6.77% | Dec 2, 2024 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|